title: The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
abstract: OBJECTIVE
  To study the effect of fluconazole on the steady-state pharmacokinetics of the protease inhibitors ritonavir and saquinavir in HIV-1-infected patients.
  
  
  METHODS
  Five subjects treated with saquinavir and three with ritonavir received the protease inhibitor alone (saquinavir 1200 mg three times daily, ritonavir 600 mg twice daily) on day 1, and the same protease inhibitor in combination with fluconazole (400 mg on day 2 and 200 mg on days 3 to 8). Pharmacokinetic parameters were determined on days 1 and 8.
  
  
  RESULTS
  In the saquinavir group, the median increase in the area under the plasma concentration vs time curve was 50% from 1800 microg l(-1) h to 2700 microg l(-1) h (P = 0.04, median increase: 900 microg l(-1) h; 2.5 and 97.5 percentile: 500-1300), and 56% for the peak concentration in plasma (from 550 to 870 microg l(-1), P = 0.04; median increase: 320 microg l(-1) h, 2.5 and 97.5 percentile: 60-450 microg l(-1)). In the ritonavir group, there were no detectable changes in the pharmacokinetic parameters on addition of fluconazole.
  
  
  CONCLUSIONS
  Because of the favourable safety profile of saquinavir, dose adjustments are probably not necessary with concomitant use of fluconazole, as is the case for ritonavir.
authors: Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands. Apkko@slz.nl
authors: C H
authors: CH
authors: Koks
authors: K M
authors: KM
authors: Crommentuyn
authors: R M
authors: RM
authors: Hoetelmans
authors: D M
authors: DM
authors: Burger
authors: P P
authors: PP
authors: Koopmans
authors: R A
authors: RA
authors: Mathôt
authors: J W
authors: JW
authors: Mulder
authors: P L
authors: PL
authors: Meenhorst
authors: J H
authors: JH
authors: Beijnen
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics*; D000935:Antifungal Agents / Q000494:pharmacology; D019540:Area Under Curve; D001682:Biological Availability; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism*; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics; D015497:HIV-1; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D008954:Models, Biological; D019438:Ritonavir / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019258:Saquinavir / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D013997:Time Factors
chemical_list: D019380:Anti-HIV Agents; D000935:Antifungal Agents; D017320:HIV Protease Inhibitors; D015725:Fluconazole; D019258:Saquinavir; D019438:Ritonavir